Cohance Lifesciences shares hit fresh 52-week low, plunge 9% after sharp decline in Q3 net profit

Shares

of Cohance Lifesciences Ltd declined nearly 9% to hit a fresh 52-week low in morning trade on Friday, February 13, a day after the Hyderabad-based company reported a sharp decline in net profit and revenue for the December 2025 quarter.

The pharma stock opened lower at ₹321.45 apiece, down 8.31% from its previous close of ₹350.6, on the BSE on Friday. Shares of the company further plunged as much as 8.95% to hit a fresh 52-week low of ₹319.2 apiece.

The decline in stock price was seen after the company reported a huge drop in net profit for the third quarter of the current financial year (Q3FY26). In its financial results for the December quarter, released post-market hours on Thursday, Cohance Lifesciences reported a 76% year-on-year drop in net profit to ₹36.7 crore, compared to ₹153 crore in Q3FY25. The company’s consolidated revenue from operations dropped 19.5% YoY to ₹544.5 crore in Q3FY26 from ₹676.2 crore in the year-ago period.

Cohance Lifesciences reported a nearly 60% drop in Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) to ₹96.8 crore against ₹239.7 crore in Q3FY25, while margins stood at 15.6% in the December 2025 quarter, down from 38.7% in the same quarter of the preceding fiscal.

"FY26 represents a transition and bottoming phase, driven by portfolio mix changes, customer-led inventory normalisation and timing shifts across select programmes," the company said in its investor presentation.

Cohance Lifesciences also revised its FY26 revenue guidance to an early-to-mid double-digit decline, reflecting incremental timing effects compared to the earlier flat outlook.

For the 9-month period ended December 2025, the company reported a 6.7% YoY drop in consolidated revenue from operations at ₹164.94 crore against ₹176.81 crore in the year-ago period. Its net profit plunged over 56% YoY to ₹159.7 crore during the period under review, while EBITDA declined 41.8% to ₹331.8 crore.

Shares of Cohance Lifesciences recovered some of their early losses to trade at ₹329.05 apiece, down 6.15%, on the BSE at 12 pm.